LL28
Coherus Biosciences (NASDAQ:CHRS) reported promising overall survival data from a Phase 3 study for its drug candidate toripalimab in the treatment of an aggressive head and neck cancer.
The study tested toripalimab in combination with the chemotherapy drugs gemcitabine and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. The results were presented at the annual meeting of the American Society for Clinical Oncology.
Coherus said the Phase 3 study showed overall survival in the study was 36 months, with 33.7 months observed in the chemotherapy only arm and median overall survival not yet reached in the toripalimab arm.
The two-year survival rate for toripalimab plus chemotherapy compared with chemotherapy only was 78% vs. 65.1%, while the three-year survival rate was 64.5% vs. 49.2%. The study consisted of 146 patients in the toripalimab plus chemotherapy arm and 143 patients in the chemotherapy only arm, according to Coherus.
Coherus’s biologics license application for toripalimab is currently being reviewed by the US Food and Drug Administration. The company said Monday that it anticipates potential approval for the drug in Q3, followed by a US launch.
More on Coherus:
ASCO 2023: What to look for at oncology’s biggest meeting
Mark Cuban online pharmacy to offer AbbVie Humira biosimilar
Coherus BioSciences falls after regulatory update on cancer drug
